Sector News

Roche to exit $75M diagnostics development deal with PacBio

December 19, 2016
Life sciences

Three years ago, Pacific Biosciences stock leaped 73% on the news of a product development deal with Roche that saw the latter forking over $35 million up front. Now, the pair is calling it quits, freeing up PacBio to sell its tech in any market and Roche to focus on other projects.

Under the deal, originally inked in September 2013, Pacific Biosciences would develop diagnostic products, such as those for gene sequencing, and license them exclusively to Roche’s diagnostics unit. Roche would secure exclusive rights to distribute the products worldwide in the field of in vitro diagnostics, while PacBio would retain the rights to market in every field other than human in vitro diagnostics. The products would be based on PacBio’s Single Molecule, Real-Time (SMRT) platform and PacBio stood to collect up to $40 million in milestone payments.

The agreement allowed Roche to exit the partnership for any reason within 60 days’ notice. PacBio shares dropped more than 38% Thursday morning, after Roche announced its exit. During the collaboration, the duo developed the Sequel System, a sequencing platform it debuted in September last year that met all of the milestones declared in the agreement, said PacBio CEO Dr. Michael Hunkapiller, in a statement.

“As a result of this decision we will have greater focus on our internal development efforts and drive our long term strategy which is to be a leader in clinical diagnostic sequencing,” said Neil Gunn, Head of Roche Sequencing Solutions, in a statement. “We are continuing to actively pursue multiple technologies and commercial strategies internally and externally to ensure we address the specific needs of our customers in the clinical diagnostic sequencing market segment.”

PacBio is putting on a brave face: “While we are disappointed with Roche’s decision to terminate the agreement, we are already familiar with this market and Roche’s decision does not significantly change our near-term plans for expanding our business to address this market,” Hunkapiller said.

Roche had planned to develop targeted assays and software for the Sequel System under the agreement. Now that Roche has exited the deal, PacBio will now “immediately” focus on other opportunities in the clinical research and sequencing space that don’t require assay-specific kits, Hunkapiller said.

Back in February, there were rumblings that Roche was considering an acquisition of PacBio.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”